Author

Bal R. Bhandari 1

1 Delta Research Partners,Monroe,United States of America

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR CROHN’S DISEASE: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

Stefan Schreiber, Corey A Siegel, Keith Friedenberg, Ursula Seidler, Bal R. Bhandari, Ziad Younes, KE WANG, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Scott D. Lee, Edward V Loftus Jr

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romańczyk, Hao Chai, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Satish Keshav, Silvio Danese

EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

William Sandborn, Marc Ferrante, Bal R. Bhandari, Geert R. D'Haens, Elina Berliba, Brian G. Feagan, Paul Klekotka, Janelle Laskowski, Michael Durante, Jay Tuttle, April Naegeli

Item 1 - 3 / 3
1